These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33550292)

  • 1. Dual Blockade of the Renin-Angiotensin System: A Strategy that Should Be Reconsidered in Cardiorenal Diseases?
    Mei M; Zhou Z; Zhang Q; Chen Y; Zhao H; Shen B
    Nephron; 2021; 145(2):99-106. PubMed ID: 33550292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined blockade of the renin-angiotensin system].
    Azizi M
    Bull Acad Natl Med; 2014 Feb; 198(2):351-62; discussion 362. PubMed ID: 26263709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
    Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is there still a place for a dual blockade of the renin-angiotensin system in 2012?].
    Krzesinski JM; Scheen AJ
    Rev Med Suisse; 2012 Aug; 8(351):1598-603. PubMed ID: 22988713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.
    Arici M; Erdem Y
    Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
    Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
    Saglimbene V; Palmer SC; Ruospo M; Natale P; Maione A; Nicolucci A; Vecchio M; Tognoni G; Craig JC; Pellegrini F; Lucisano G; Hegbrant J; Ariano R; Lamacchia O; Sasso A; Morano S; Filardi T; De Cosmo S; Pugliese G; Procaccini DA; Gesualdo L; Palasciano G; Johnson DW; Tonelli M; Strippoli GFM;
    J Am Soc Nephrol; 2018 Dec; 29(12):2890-2899. PubMed ID: 30420421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
    Rastogi A; Rashid M; Wright RF
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.